Therapy Detail

Therapy Name Temozolomide
Therapy Description

Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Temozolomide Temodar Methazolastone Chemotherapy - Alkylating 14 Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MSH6 T1219I glioblastoma multiforme resistant Temozolomide Preclinical Actionable In a preclinical study, glioblastoma cells harboring a MSH6 T1219I mutation were resistant to Temodar (temozolomide) in cell culture (PMID: 19584161). 19584161
Clinical Trial Phase Therapies Title Recruitment Status
NCT02655601 Phase Ib/II BMX-001 + Temozolomide Temozolomide Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Recruiting
NCT01409174 Phase Ib/II Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alfa-2b IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Terminated
NCT02052648 Phase Ib/II Temozolomide indoximod Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Active, not recruiting
NCT02617589 Phase III Nivolumab Temozolomide Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498) Recruiting
NCT02530502 Phase Ib/II Temozolomide Pembrolizumab Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT02340156 Phase II SGT-53 Temozolomide Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma Recruiting
NCT02023905 Phase II Temozolomide Everolimus Everolimus With and Without Temozolomide in Adult Low Grade Glioma Active, not recruiting
NCT00492687 Phase II Carboplatin Temozolomide Tamoxifen Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status
NCT02414165 Phase II Bevacizumab Lomustine Toca 511 + Toca FC Temozolomide P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) Active, not recruiting
NCT01638546 Phase II Temozolomide Veliparib Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Completed
NCT02392793 Phase I Irinotecan + Talazoparib Temozolomide Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies Active, not recruiting
NCT03607643 Phase Ib/II Temozolomide Bevacizumab + FOLFIRINOX Bevacizumab + Cannabidiol + FOLFIRINOX Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Not yet recruiting
NCT02343406 Phase II Lomustine Depatuxizumab mafodotin Temozolomide ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Recruiting
NCT02502708 Phase I indoximod Temozolomide Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors Recruiting
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
NCT01514201 Phase Ib/II Temozolomide Veliparib Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Completed
NCT01800695 Phase I Temozolomide Depatuxizumab mafodotin Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme Completed
NCT02667587 Phase II Temozolomide Nivolumab + Temozolomide Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer). Active, not recruiting
NCT02152982 Phase II Veliparib Temozolomide Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Active, not recruiting
NCT01790503 Phase Ib/II Pexidartinib Temozolomide A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT02311920 Phase I Temozolomide Nivolumab Ipilimumab Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Active, not recruiting
NCT02446704 Phase Ib/II Olaparib Temozolomide Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Recruiting
NCT02510950 Phase I Sargramostim poly ICLC Temozolomide Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Terminated
NCT03576612 Phase I AdV-tk Temozolomide Valacyclovir Nivolumab GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (GMCI) Recruiting
NCT02573324 Phase II Depatuxizumab mafodotin Temozolomide A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Recruiting
NCT02315534 Phase Ib/II Napabucasin Temozolomide A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma Active, not recruiting
NCT02010606 Phase I Bevacizumab Temozolomide Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma Active, not recruiting
NCT02137759 Phase II Vorinostat Temozolomide MRSI to Predict Response to RT/TMZ and Vorinostat in GBM Recruiting
NCT03425292 Phase I Temozolomide Nivolumab + Ipilimumab Nivolumab A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer Recruiting
NCT02977780 Phase II CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) Recruiting
NCT01430351 Phase I Temozolomide Memantine Metformin Mefloquine Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM) Active, not recruiting
NCT02179086 Phase II Temozolomide Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting
NCT01835145 Phase II Dacarbazine Temozolomide Cabozantinib Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye Completed
NCT01390948 Phase II Temozolomide Bevacizumab A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma Active, not recruiting